[
    [
        {
            "time": "2018-09-01",
            "original_text": "Pfizer’s Revenue and EPS Growth Rate",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Revenue",
                    "EPS",
                    "Growth Rate"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-01",
            "original_text": "What’s Driving Pfizer’s Revenue?",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Revenue",
                    "Driving"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-01",
            "original_text": "Dow Movers: NKE, IBM",
            "features": {
                "keywords": [
                    "Dow",
                    "Movers",
                    "NKE",
                    "IBM"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-09-01",
            "original_text": "A Look at Pfizer’s Performance So Far in September",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Performance",
                    "September"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-27",
            "original_text": "Prestige Consumer Healthcare Inc. (PBH) Ex-Dividend Date Scheduled for September 27, 2018",
            "features": {
                "keywords": [
                    "Prestige",
                    "Consumer",
                    "Healthcare",
                    "Ex-Dividend",
                    "Date",
                    "Scheduled"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-09-01",
            "original_text": "Analyzing Perrigo’s Prescription Pharmaceuticals Business",
            "features": {
                "keywords": [
                    "Perrigo",
                    "Prescription",
                    "Pharmaceuticals",
                    "Business"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-09-01",
            "original_text": "A Closer Look at the Allergan–Bonti Deal",
            "features": {
                "keywords": [
                    "Allergan",
                    "Bonti",
                    "Deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]